Skip to content

Chemotherapy-free ATO/ATRA regimen improves survival in APL, but patient age is a crucial factor
Dr. Ying Huang presents first-in-human data for in vivo CAR-T LB2501 in B-cell NHL
Liso-cel plus ibrutinib induces deep remissions in patients with relapsed or refractory CLL/SLL
Partnership expands access to CLL treatment in low-, middle-income countries
Phase 1 data reported for anti-CD123 CAR T-cell therapy in relapsed or refractory AML, BPDCN

Insider Reader Survey

Join SOHO

Follow Us :

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

Thomas Martin, MD

Cellular Therapy

Thomas Martin, MD

Leukemia

Thomas Martin, MD

Lymphoma

Thomas Martin, MD

Multiple Myeloma

Thomas Martin, MD

Myelodysplastic Syndromes

Thomas Martin, MD

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

August 25, 2026

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

SOHO Insider Thomas Martin, MD

Thomas Martin, MD

by sohonews
October 16, 2024
0 Comments
Less than a minute
781 Views
2 years ago

Share This Post:

Facebook Twitter Pinterest Whatsapp Cloud StumbleUpon Print Share via Email

Related Post

older adult patient

Leukemia, Acute Myeloid Leukemia, News

Chemotherapy-free ATO/ATRA regimen improves survival in APL, but patient age is a crucial factor

August 24, 2026

EHA 2026, Cellular Therapy, Lymphoma, Aggressive B-Cell Lymphomas, News, Video Interviews

Dr. Ying Huang presents first-in-human data for in vivo CAR-T LB2501 in B-cell NHL

August 21, 2026

Cellular Therapy, Leukemia, Chronic Lymphocytic Leukemia, Lymphoma, Indolent B-Cell Lymphomas, News

Liso-cel plus ibrutinib induces deep remissions in patients with relapsed or refractory CLL/SLL

August 20, 2026

a globe

Leukemia, Chronic Lymphocytic Leukemia, News

Partnership expands access to CLL treatment in low-, middle-income countries

August 19, 2026

SOHO 2026, Cellular Therapy, Leukemia, Acute Myeloid Leukemia

Phase 1 data reported for anti-CD123 CAR T-cell therapy in relapsed or refractory AML, BPDCN

August 18, 2026

EHA 2026, Lymphoma, Aggressive B-Cell Lymphomas, Video Interviews

Drs. Georg Lenz and Loretta Nastoupil discuss phase 3 FRONTMIND study

August 17, 2026

Top Categories

Cellular Therapy

79

Leukemia

126

Lymphoma

140

Multiple Myeloma

118

Myelodysplastic Syndromes

44

Myeloproliferative Neoplasms

35

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Thomas Martin, MD

Cellular Therapy

Thomas Martin, MD

Leukemia

Thomas Martin, MD

Lymphoma

Thomas Martin, MD

Multiple Myeloma

Thomas Martin, MD

Myelodysplastic Syndromes

Thomas Martin, MD

Myeloproliferative Neoplasms

Subscribe

Recent Posts

older adult patient

Chemotherapy-free ATO/ATRA regimen improves survival in APL, but patient age is a crucial factor

Dr. Ying Huang presents first-in-human data for in vivo CAR-T LB2501 in B-cell NHL

Liso-cel plus ibrutinib induces deep remissions in patients with relapsed or refractory CLL/SLL

Copyright © 2026 Society of Hematologic Oncology, All rights reserved.